Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "ALK: A Tyrosine Kinase Target for Cancer Therapy"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 11027
Special Issue Editors
Interests: circulating tumor cells; extracellular vesicles; microfluidic technologies; lung cancer; single-cell technologies
Interests: lung cancer, circulating biomarkers, circulating tumor cells, immunotherapies
Special Issue Information
The anaplastic lymphoma kinase (ALK) gene located on chromosome 2 encodes for a protein that is crucial for neuronal development. The ALK gene has been found to be rearranged, mutated, or amplified in cancers, including anaplastic large-cell lymphomas, neuroblastomas, and lung adenocarcinomas.
Despite tremendous progress in the clinical development of tyrosine kinase inhibitors that target oncogenic ALK, the responses are temporary, with the development of resistance within 1–2 years. There is much work to be done to understand the early events that underpin the transformation of ALK-rearranged or -mutated cancers, the clonal evolution of these cancers, and the development of resistance, as well as identifying newer therapies including those that target the removal of proteins (e.g., proteolysis targeting chimera, PROTAC) rather than targeting the receptor itself. Additionally, these cancers are seldom responsive to the usual immunotherapeutic strategies that involve immune checkpoint inhibition, and more work is needed to identify and target specific mechanisms of immune evasion of these cancers. These studies may allow earlier intervention and allow more durable responses and eventually cures for this subgroup of patients with aggressive cancers.
In this Special Issue, we explore the current understanding of the pathobiology of these unique cancers, therapy options, and blood-based modalities for diagnosis and monitoring, as well as how they complement initial tumor biopsies and offer potential solutions to unanswered questions in the field. We hope to generate enthusiasm within the cancer community to hasten progress in the approach to these rare but aggressive cancers.
Dr. Sunitha Nagrath
Dr. Nithya Ramnath
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- ALK rearrangement
- lung cancer
- tyrosine kinase inhibitors